Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years

Br J Haematol. 2020 Apr;189(1):e13-e16. doi: 10.1111/bjh.16410. Epub 2020 Feb 26.

Authors

Affiliations

¹ Uppsala University Hospital, Uppsala, Sweden.
² Linköping University Hospital, Linköping, Sweden.
³ Linköping University, Linköping, Sweden.
⁴ Karolinska University Hospital, Stockholm, Sweden.
⁵ Skåne University Hospital, Lund, Sweden.
⁶ Umeå University, Umea, Sweden.
⁷ Sahlgrenska University Hospital, Gothenburg, Sweden.
⁸ Karolinska Institute, Stockholm, Sweden.
⁹ Örebro University, Orebro, Sweden.
¹⁰ Sahlgrenska Academy, Gothenburg, Sweden.
¹¹ Sundsvall Hospital, Sundsvall, Sweden.
¹² Lund University, Lund, Sweden.

PMID: 32103493
DOI: 10.1111/bjh.16410

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Azacitidine / administration & dosage
Cytarabine / administration & dosage
Decitabine / administration & dosage
Disease-Free Survival
Female
Follow-Up Studies
Humans
Hydroxyurea / administration & dosage
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / mortality
Male
Middle Aged
Retrospective Studies
Survival Rate

Substances

Cytarabine
Decitabine
Azacitidine
Hydroxyurea